Table 5. References for studies on induction chemotherapy.
| ICT | Study | LRC | DC | Response | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Arms | 2-yr LRC | Diff in LRC | 3-yr DC | 5-yr DC | Diff in DC | Overall Resp | Diff in Resp | ||||
| ICT vs. Surg | Wolf et al. (25) | A. ICT –> RT | 92%, ns | B>A, P=0.0005 | 89%, ns | – | A>B, P=0.016 | – | None reported | |||
| B. Surg –> RT | 95%, ns | 83%, ns | – | – | ||||||||
| Lefebvre et al. (26) | A. ICT –> RT | None reported | 72% | 65% | A>B, P=0.041 | – | None reported | |||||
| B. Surg –> RT | 57% | 52% | – | |||||||||
| Forastiere et al. (3) | A. ICT –> RT | 61% [54–69] | B>A, P=0.003 | 91%, 2-yr DC | 85% | B>C, P=0.03 | – | – | ||||
| B. CRT | 78% [72–85] | A vs. C, P=0.16 | 92%, 2-yr DC | 88% | – | – | ||||||
| C. RT alone | 56% [48–63] | B>C, P<0.001 | 84%, 2-yr DC | 78% | – | – | ||||||
| ICT vs. CRT alone | Haddad et al. (27) | A. ICT –> CRT | 84%, ns | None reported | 93%, ns | – | None reported | – | – | |||
| B. CRT alone | 85%, ns | 89%, ns | – | – | – | |||||||
| Cohen et al. (28) | A. ICT –> CRT | 70% | P=0.16 | – | 62% | P=0.37 | 74% | P=0.45 | ||||
| B. CRT alone | 60% | – | 60% | 79% | ||||||||
| Ghi et al., Abstract (30) | A. ICT –> CRT | – | – | – | – | – | – | – | ||||
| B. CRT alone | – | – | – | – | – | – | – | |||||
| Stokes et al. (31) | A. ICT –> CRT | – | – | – | – | – | – | – | ||||
| B. CRT alone | – | – | – | – | – | – | – | |||||
| Chen et al. (32) | A. CRT alone | – | – | – | – | – | ||||||
| B. ICT +/− RT/CRT | – | – | – | – | – | |||||||
| C. ICT +/− RT/CRT | – | – | – | – | – | |||||||
| Ock et al. (33) | A. ICT –> CRT | 69% (3-yr) | P=0.11 | 89% | – | P=0.85 | 76% | A>B, P=0.005 (matched) | ||||
| B. CRT alone | 59% (3-yr) | 87% | – | 53% | ||||||||
| Merlano et al., ongoing (34) | A. ICT –> CRT | – | – | – | – | – | – | – | ||||
| B. CRT alone | – | – | – | – | – | – | – | |||||
| Yang et al. (35) | A. ICT –> CRT | 88% (5-yr) | P=0.21 | 86% | 83% | A>B, P=0.014 | – | – | ||||
| B. CRT alone | 85% (5-yr) | 82% | 73% | – | – | |||||||
| Zhang et al. (36) | A. ICT –> CRT | 92% (3-yr) | None reported | 91% | – | None reported | 97% | None reported | ||||
| B. CRT alone | 91% (3-yr) | 84% | – | 97% | ||||||||
LRC, locoregional control; DC, distant control; ICT, induction chemotherapy; CRT, chemoradiation; RT, radiotherapy; Diff, difference; Resp, response; Surg, surgery; TPF, docetaxel-platinum-5-fluorouracil (docetaxel 75 mg/m2 on day 1, cisplatin 75–100 mg/m2 on day 1, 5-fluorouracil 750–1,000 mg/m2 on days 1–4 as continuous infusion; 3–4 cycles on 21-day interval); PF, platinum-5-fluorouracil (cisplatin 80–100 mg/m2 given as rapid intravenous infusion followed by 5-fluorouracil 800–1,000 mg/m2/day continuous 24-hour infusion for 5 days; 2–4 cycles on 21-day interval).